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 Research proposal 
Title: 
Serum bactericidal activity of colistin against Acinetobacter baumannii in patients with normal 
versus impaired renal function. 
Aims: 
The aim of this study will be to determine whether the adjusted doses of colistin
methanesulphonate recommended for treatment of patients with renal impairment will result in
the same or similar serum bactericidal titres as those achieved using the doses recommended for 
patients with normal renal function. The hypothesis is that the use of ‘adjusted doses’ of colistin
methanesulphonate result in significantly reduced serum bactericidal activity.
Background: 
There has been a worldwide increase in the number of infections caused by multi-drug resistant
gram negative bacteria such as Klebsiella pneumoniae, Pseudomonas aeruginosa and 
Acinetobacter baumanii. This has led to an increased use of the polymyxins such as colistin
methanesulphonate. These are often the only effective antibiotics available.
There are currently no standardized dosing regimens for colistin in critically ill patients with
renal impairment requiring dialysis (9). Current dosing in patients with various degrees of renal
impairment are not supported by adequate evidence. Anecdotal observations of therapeutic 
failure in patients with renal impairment, have led to a concern that patients are being under-
dosed. In contrast, clinical experience shows that patients without renal failure who have 
Acinetobacter baumanii infections respond to the maximum recommended doses of colistin
methanesulphonate (Sanofi-Aventis product information for Coly-Mycin® M, 1996). This study
undertakes to determine whether current dosage recommendations in renal failure are sub-
optimal by comparing in-vitro serum bactericidal titres of patients receiving standard versus 
renally adjusted doses of colistin methanesulphonate.
Colistin has been available for use since the early 1960’s but fell out of favour due to concerns 
regarding toxicity. Interest in colistin has resurged in the past ten years due to problems with pan 
drug-resistant bacteria as well as new encouraging information about its toxicity profile (4). The 
main toxicities described with parenteral use include nephrotoxicity and neurotoxicity which 
may be avoided if correct doses are used. These effects appear to be temporary and subside with 
a reduction in the dose or discontinuation of the drug (5, 12). Recent studies have revealed that 
colistin is not as nephrotoxic as previously believed and actually has a more favorable profile in 
terms of nephrotoxicity than the aminoglycosides (9). Dosing guidelines have not been 











morbidities (6). There is also a paucity of information regarding the appropriate dosing regimens 
for patients requiring intermittent haemodialysis or continuous renal replacement therapy (9). 
The Coly-Mycin® product information from Sanofi-Aventis has guidelines on dosing in renal 
failure based on studies by Kucers and Bennet published in a textbook published in 1987. A data 
search failed to reveal any convincing new information.  
Colistin: 
Colistin is a polymyxin antibiotic consisting of two components: colistin A (polymyxin E1) and 
colistin B (polymyxin E2). Two different pharmacological formulations of colistin are available 
commercially. The first, colistin sulphate, is for oral and topical use. The second, less toxic form,
is sodium colistimethate (colistimethate) which is also known as colistin methanesulphonate (6,
7). The terms colistin and colistimethate are not interchangeable. Colistimethate is chemically
prepared from colistin. Colistimethate is not stable in-vitro or in-vivo, and is hydrolyzed when in
aqueous solution at 37 degrees, e.g., in plasma or broth, to a series of derivatives plus colistin,
which has increased antibacterial activity (7, 9).
Pharmacokinetics of colistin: 
The rate of hydrolysis depends on physical conditions such as pH and temperature (10). A recent
pharmacokinetic study involving cystic fibrosis patients showed the half-life of colistimethate to
be 2.1hrs, and that of colistin to be 4.2 hrs (10). In a patient undergoing continuous venovenous 
haemodialysis (CVVHD), conversion of colistimethate to colistin was rapid and the half-lives of
colistimethate and colistin were 6.8 and 7.5hrs respectively (15). The protein binding capacity of
colistin is reported as being low. A study in rats found that protein binding was about 55% in rat
plasma (14). Peak serum levels after intravenous administration occur within 10min. Higher peak 
levels occur in patients with renal failure (10).
Pharmacodynamics of colistin: 
Colistin has rapid bactericidal activity, and is bactericidal in a concentration-dependent manner 
(7, 11). Studies on the post antibiotic effect (PAE) of colistin have shown some concerning 
results indicating that even at high MIC’s there may be hetero-resistant sub-populations in a 
number of the strains studied. The strains also showed unfavorable, unexplainable negative 
PAE’s (11) suggesting that mono-therapy or extended-interval dosage regimens (e.g., 24 hours)
may not be optimal (11).
Dosing of colistin: 
The dose of colistin methanesulphonate (Coly-Mycin®) is expressed in international units (IU).  
One ampoule contains 80mg which is equivalent to 1 million IU. Recent anecdotal treatment 
failures in many institutions have resulted in an increase of colistin doses in all categories of 
renal function. This has however not yet been validated (Table 1). The concern with this increase 
in dosage is a concomitant increase in side effects particularly nephrotoxicity as reported in a 
study using similarly higher dose regimens (12). In patients with renal failure it is possible that 
failure of colistin therapy could be due to inadequate drug levels in patients adjusted doses. 
The Serum Bactericidal Test (SBT):  
This is an in-vitro test that attempts to measure the in-vivo activity of an antimicrobial agent. The 











organism is the serum bactericidal titre. This method of testing incorporates the 
pharmacodynamic and pharmacokinetic properties of the antimicrobial agent in question (1). 
The clinical relevance of SBT testing is sometimes questioned. A study performed at the 
National Taiwan University Hospital undertook to determine the predictive value of the SBT for 
mortality in patients infected with multi-drug-resistant A.baumannii (11). Patients were treated 
with various antibiotics/antibiotic combinations including carbapenems, ciprofloxacin, 
aminoglycosides and sulbactam. Colistin was not used in this study. The authors showed that 
peak serum bactericidal titre negatively correlated with mortality rate (correlation coefficient -
0.43). The survival rate in patients with peak SBT titres of ≥16, ≥8, ≤4 was 100%, 87.5% and 
42.4% respectively (p=0.001). Given this strong association, we believe that it will be valid and 
clinically relevant to compare SBT’s in patients on standard and adjusted doses of colistin in 
order to determine the efficacy of adjusted renal dosage (11).  
Study population: 
Inclusion criteria: 
All patients commenced on colistin treatment for proven or suspected Acinetobacter baumannii
infection will prospectively be enrolled. Patients will be recruited from the medical and surgical
Intensive Care Units at Groote Schuur Hospital in Cape Town, South Africa. These are typically
patients who have an A. baumannii isolated from any body site that suggests infection and 
requires treatment, e.g., ventilator associated pneumonia. It is well known that culture of this 
organism from many sites may represent colonization rather than infection. Thus only patients 
who have an infection for which therapy is clinically indicated will be included in the study. This 
decision will be made by the attending physician. The reason for admission and diagnosis will
not impact on inclusion.
Exclusion criteria: 
1. Patients who have lipaemic or haemolysed serum. This could affect the interpretation
of SBT’s, these being determined according to visual turbidity.
2. Patients who decline consent to participation.
There will be two study groups. Firstly, patients without renal impairment, i.e., normal creatinine 
clearance. This will be defined as a creatinine clearance of > 90 ml/min for the purposes of this 
study (Group 1). These patients will be on the highest dose of colistin recommended for normal 
renal functions as stated in Table 1. Secondly, patients with impaired renal function on adjusted 
doses of colistin (Group 2).  
Materials and Methods: 
Sample Collection: 
Colistin will be commenced in enrolled patients according to the recommended dosing regimen 
(highest dose of Coly-Mycin®) at Groote Schuur Hospital as stated in Table 1. Initial blood 











Venipuncture will be performed by a phlebotomist, and a minimum of 1mL of blood will be 
drawn into a clot activated tube. 
Group 1: doses are given every 8 hours. Thus blood will be taken at 30 minutes, 60 minutes, 90 
minutes (near the peak level), then at 4 hours and 8 hours (trough level before the next dose is 
given). 
Group 2: dose frequency varies according to degree of renal impairment. Blood will be taken at 
30 minutes ,60 minutes and 90 minutes and then will be drawn every 4 hours until the next dose 
is due i.e., at 4 hours, 8 hours and 12 hours (trough level) if the dose frequency is 12 hourly. 
Degree of renal impairment, dose adjustment and type of dialysis, if utilized, will be documented 
in all cases.  
Following collection, the blood samples will be immediately placed on ice (to terminate the 
conversion of colistimethate to colistin) and taken directly to the laboratory, where serum will be 
separated from the red blood cells in a refrigerated centrifuge and subsequently frozen at -70 C.
It has been shown that colistin is stable when frozen (8).
Table 1. Dosing Schedule 











3 million U 8 hourly 1-2 million U 8 hourly
50-90 3 million U 12 hourly 2 million U 12 hourly 
10-50 3 million U daily 2 million U daily 
<10 3 million U 36 hourly 2 million U 36 hourly 
Anuric 1.5 million U after each episode 
of dialysis 
1 million U after dialysis 
CVVHD 3 million units 12 hourly (15) 2-3 million 48 hourly (9)
Laboratory Materials: 




• Eppendorf tubes 2ml
• Mueller-Hinton agar: needed for SBT determination
• Acinetobacter baumannii reference strain: The ATCC BAA-1605 strain available, which is
sensitive to amikacin and tobramycin, will not be used as amikacin is widely prescribed











strain is resistant to all antibiotics tested except colistin and tobramycin. In no clinical 
situation will these two medications be used together. The degree of resistance will be 
characterized (by doing Minimum Inhibitory Concentration testing using an Epsilometer 
E-TEST). This standard strain will be used to ensure that results can be compared to each
other with no bias due to variation in strain MIC.
• Plastic pipettes 3ml
• Tripticase soya broth (TSB)
• 2% blood agar
Methods: 
The samples will be tested individually to prevent premature thawing at room temperature.  
Testing will be performed in sterile, plastic, flat-bottomed MICROLON ® microplate 96 well 
trays (Lasec SA, South Africa). The reference strain used will be stored at -70°C in a 
MicrobankTM vial containing cryopreservative fluid. 
Inoculum preparation and inoculation of wells:
The CLSI (Clinical and Laboratory Standards Institute) recommends that the final inoculum of
reference strain in each test well is 5 x 105 cfu/ml. In order to achieve this concentration,
preparation of the reference strain is required, as follows.
1. First, the reference strain of Acinetobacter baumannii will be subcultured three times on
standard blood agar plates to ensure that the organism has optimal growth and metabolic 
status prior to drug exposure (13).
2. Next, suspensions of the organism with a turbidity equivalent to that of a 1 McFarland
standard will be prepared after suspending the colonies into a pre-warmed (35°C) 
Tripticase Soya Broth (TSB -Greenpoint NHLS Media Laboratory, South Africa). This 
will then be incubated for 6 hours to ensure log-phase growth.
3. Finally, the reference strain will be diluted to achieve the optimal concentration. As a 1 
Mcfarland standard contains approximately 3 x 108 cfu/ml, and the final concentration of
the reference strain in each well once inoculated should be 5 x 105 cfu/ml, a 1:30 dilution
of the 1 McFarland standard will be performed by adding 0.1ml of the reference strain
suspension to 2.9ml of broth. This will yield an inoculum density of 1 x 107 cfu/ml,
which will be further diluted 1:20 by adding 5ul of this organism suspension to the 100ul
(serum/TSB mixture) in the test well. This will yield a final inoculum of 5 x 105 cfu/ml in
each well.
For each timed sample from a patient e.g. patient A initial sample, a single row of a microwell 
plate (MWP) will be used, with one MWP per patient. Firstly, 100uL of TSB will be dispensed 
into wells 1-2 and 4-10 in a single row. Next, 5uL of ATCC strain will be dispensed into the 1st 
TSB-containing well, which will serve as the positive growth control. The second well will serve 
as the negative growth control. Into the 3rd and 4th wells, 100uL of neat serum will be dispensed. 
Serial doubling dilutions will begin from the 4th well using standard techniques with the final 
well for every sample being a 1:128 dilution. Next 5uL of the ATCC strain will be added to 
wells 3 to 10, achieving a final volume of 105uL in all 10 wells. According to the NCCLS 
document the volume of organism suspension added to the well must not exceed 10% of the total 











For the next row, the above method will be repeated for the next timed sample collected from the 
same patient e.g. patient A 30 min draw. Once all the rows have been inoculated for a patient 
(depending on the number of samples collected per patient), the microwell plate will be 
incubated in air at 35°C for 18-24 hours. 
Reading of results:  
Wells will only be read if there is definite turbidity in the positive growth control and no growth 
in the negative growth control. Twenty microlitres of fluid from every well containing no growth 
will be sub-cultured onto Mueller-Hinton agar to assess the bactericidal activity of the drug. The 
plates will be incubated in air at 35°C for 18-24 hours. The dilution that demonstrates 99.9% 
killing, i.e., 20ul of the 5 X 105 cfu/ml dilution should contain fewer than 10 colonies on the 
plate, is the bactericidal titre.  
Analysis and Interpretation of results:
The serum bactericidal activity will be assessed against a known (reference strain) of
Acinetobacter baumannii. Titres of patients receiving dosages of colistin recommended for 
normal renal function will be compared to those receiving adjusted dosages due to renal
impairment.
Subgroup analysis will be performed to evaluate the effect of dialysis on the SBT, however the 
study will not specifically be powered for this analysis. Additional factors which may influence 
SBT, such as age and type of illness will be recorded.
Bacterial eradication in vitro cannot predict clinical cure. Many factors play a role including: 
host factors, post-antibiotic effect and growth-inhibitory effects of sub-MIC concentrations (13).
If results show that the titres achieved in the renal failure patient group are much lower than
those of the normal renal function group, further studies will be needed to determine what dose 
increase is required as the risk of drug toxicity is a major concern.
 Limitations: 
• Inability to directly determine the serum concentration of colistin achieved with a 
particular dose
• Although SBT predicts bacterial eradication, the clinical relevance of SBT remains 
controversial (13). In-vitro bacterial eradication cannot predict clinical cure.
• Biological assays such as this are unable to differentiate the amount of colistin present
in the sample at the time of collection from the colistin formed in vitro by hydrolysis
of colistimethate during the microbiological assay (2); however, bias will be
minimized by treating all samples in the same manner.
• It has been documented that human serum alone can have a bactericidal effect on
certain Acinetobacter baumannii strains due to complement mediated lysis (3). This
may have a confounding effect.
• Many patients will be on concomitant broad spectrum antibiotics including a
carbapenem. Other patients will recently have been on another broad-spectrum
antibiotic. Renal failure can affect clearance of these drugs and so there may
sometimes be residual antibiotic still present in the patient’s serum, thus the SBT











meropenem against Acinetobacter baumannii (14). To minimize this effect a 
characterized strain of Acinetobacter baumannii will be used that is resistant to all 
antimicrobials that may be used locally for the treatment of Acinetobacter. This strain 
will only be sensitive to colistin. This will ensure that there will be minimal effect on 
the SBT from the other antibiotics if used concomitantly.   
Sample size 
In order to determine a two-fold difference in SBT level between the two groups (standard dose 
and renal dose) with 80% power and type 1 error of 0.05, we will require 17 patients per group. 
Budget: 
The National Health Laboratory Service Research Trust will be approached as a possible source 
for the funds required.
Items required Number of units Cost per unit/box Total Cost 
Laboratory items: ------------------------ ------------------------ ---------------------- 
1. Microplate 96 wells
flat bottomed





600 R3.00 per agar plate R1800.00 
3. Pipette tips
FILTER
9000 R950.00 per 1000
tips
R8550.00 
4. 1000ul pipettes 2 +/- R4000 each R8000.00 
5. 100ul pipettes 2 +/- R3000 each R6000.00 
6. 10ul pipettes 2 +/- R3000 each R6000.00 
7. A.baumannii strain
and transport
1 R1500.00 R1500.00 
8. Safelock Eppendorf
1.5ml




1000ml R80.00 for 200ml R400.00 
10. 2% blood Agar 600 R3.50 per agar plate R2100.00 
11. Plastic pipette 3ml 1000 R75.00 per packet 
(500’s) 
R150.00 
Collection items for 
ward: 
------------------------ ------------------------ ---------------------- 
12. SST Gel tubes 5ml 300 R100.00 per box 
(100’s) 
R300.00 
13. Vac needles black 300 R75.00 per box 
(100’s) 
R225.00 




















300 R125.00 per box of 
50 
R750.00 
17. Micro pore tape 30 R10.00 R300.00 







2 for each antibiotic R1050 for a Box of 
30 – a box is needed 
for each antibiotic 
R9450.00 
 Stationery required:   R3000.00 
 TOTAL:  R52 880.00 
Ethical consideration: 
All blood samples once drawn and sent to the laboratory will be given a laboratory number and 
only this will be used for sample identification. Patient names and/or hospital numbers will not
be mentioned in the study write-up. There will thus be no breach of patient confidentiality.
Treatment with colistin will be commenced at the discretion of the attending physician. Reasons 
to institute therapy will include proven Acinetobacter baumannii infections as well as empiric 
choices in patients who are developing signs and symptoms of infection and are known to be 
colonized with the organism.
In terms of patient discomfort whilst drawing blood samples, ICU patients often require blood 
tests to be done on a daily basis. It will be discussed with staff that other blood tests that need to
be done can be done at the same time as the samples required as to minimize patient discomfort.
If repeated 4 hourly specimens are required patients will receive a port that will be present for 
the duration of the blood collection to minimize repeated venipuncture.
Consent may be difficult to obtain from the patients themselves as often the patient is unable to 
give consent and family members may not be present at the time the decision is made to 
commence therapy, e.g., sudden deterioration in patients’ condition due to sepsis. Although 
every effort will be made to get consent, this may be problematic as therapy is often started as an 
emergency intervention. Every patient who is started on colistin therapy has to have a signed 
section 21 clearance form from the Medicines Control Council as colistin is not registered for 
use in South Africa. The Medicines Control Council will be informed of this particular study.  
The results of this study will not have an impact on patient treatment as the patients own isolate 
has not been used and one thus cannot individualize dose adjustments. Future dose adjustments 












• If one were to use the patients’ own isolate and not a reference strain, one could use the
SBT as a prognostic indicator as it correlates directly with mortality and could be used as
an indicator of the need to possibly modify treatment dose in that particular patient. The
patient’s own A.baumannii isolate will be collected and stored for possible further
expansion of this study in the future.
• Collaborators in the Department of Pharmacology will explore the possibility of
establishing an assay for direct analysis of colistin and its metabolite in stored samples
from this study.
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Objectives of literature review: 
• To research the pharmacology of colistin (polymyxin E) and related polymyxins with
focus on pharmacokinetics, pharmacodynamics
• To review studies performed using colistin in different settings, patient populations and at
different doses
• To find a standardized protocol on how to perform a Serum Bactericidal Test (SBT)
• To assess the value of microbiological assays and how they compare to measuring
pharmacological levels of colistin
• To determine the gaps in colistin research
Literature search strategy: including exclusion and inclusion criteria:
From September 2008 to December 2009, the search engines PUBMED and Google Scholar 
were used. The initial search included the keywords: ‘pharmacology, colistin, polymixin,
pharmacodynamics, pharmacokinetics’. Articles in languages other than English were excluded 
from the search. Other literature included textbooks found at the University of Cape Town
Library and the Pharmacology Department at Groote Schuur Hospital in Cape Town.
Finding existing information on the pharmacology of colistin was necessary to prevent repeating 
previous studies and to inform the study design. The initial selection strategy was broad, in order
to extract as much information as possible on polymyxins, in view of the paucity of
pharmacological data on colistin itself. Many of the initial studies on colistin cited polymyxin B 
not the colistin preparation used currently, polymyxin E, which differs by a single amino acid.
Moreover it included studies in animals as well as those in cystic fibrosis patients, in whom
colistin was initially used. This was in contrast to the study population, however, it provided 
useful background to the subject. Knowledge of the antimicrobial spectrum, chemical
composition, stability at various temperatures and states e.g., in solution and in serum was 
required. Other necessary parameters included peak levels, volume of distribution, elimination
half-life as well as information on the correlates of efficacy. Knowledge on the activity of the 
drug in different settings, patient populations, at different doses was crucial in order to formulate 
a research question as well as an explanation of the findings in the population subgroups studied.
Previous studies that showed the effects of renal failure/dialysis on colistin levels and 
action/effect were searched for. Sampling required knowledge of the half-life of colistin in order 
to work out when steady-state of the drug is reached as well as information on the time after 
administration that the drug reaches a peak level.
One of the search strategies used was searching by author. This may, however, be limited by the 
author’s interests and is possibly prone to bias. 
Once the relevant articles had been retrieved by the initial broad search, the search was refined to 











patients receiving dialysis. The initial search yielded information on all the colistin preparations 
including topical and inhaled forms.  
Clarity on various pharmacological and clinical concepts such as SLED (Sustained Low 
Efficiency Dialysis) was required.  
As the SBT is not performed routinely in a clinical laboratory and the results have not been
correlated with clinical efficacy, a study that could prove its clinical utility, usefulness and 
relevance was needed. A protocol for the Serum Bactericidal Test (SBT) was found in the 
NCCLS (National Committee for Clinical Laboratory Standards) document as no updated CLSI 
(Clinical and Laboratory Standards Institute) document was available. This was used to guide 
accurate and correct performance of the SBT. Information on serum dilutions, materials required,
incubation temperatures and durations was searched for in this document to guide protocol steps 
and methodology (18), which was a variation of the typical SBT. In order to gain a broad 
perspective on serum bactericidal/ microbiological assays, studies where these tests had 
previously been performed using other drugs were helpful. This contributed to protocol
preparation and provided insight into the interpretation of the SBT in different settings.
The next objective was to find an Acinetobacter baumannii strain which met the study
requirements. Strains identified in the literature did not contain the resistance patterns that were 
required. The ATCC Bacteriology Collection also did not have such a strain. The strain chosen
was isolated from a sputum sample of a patient admitted to the Respiratory ICU at Groote
Schuur Hospital. Information on how to prepare, culture and handle the organism was found in
the SBT protocol in the NCCLS document (18).
It was important to determine patient and assay factors that influence the accuracy of the SBT, as 
well as the advantages and limitations of the microbiological assay compared with alternatives 
such as pharmacological assays.
Using existing knowledge, a list of potential confounders was drawn up, and a literature search
on “SBT” and each confounder using the advanced search field in PUBMED was performed.
With further research and reading, several new possible confounders were identified, which
expanded the original list. The protocol was adjusted according to new findings e.g., exclusions 
were included such as lipaemic/haemolyzed blood that may affect interpretation of the SBT (18).
It became apparent that the use of concurrent antibiotics had to be considered, as this may cause 
synergism or possible antagonism with colistin.  Additional metabolic and 
chemical/physiological factors that could influence the results were explored such as gender 
differences, age and volume of distribution of colistin. 
Quality criteria: appraisal of studies: 
To evaluate/rate the strength of evidence and to critically review the quality of research studies, a 
guide was required (26). The general approach to assessing research studies, articles and 
available literature required fine tuning. This was discovered when initial literature searches 











Quality research is done when there is an adequate study design, selection of subjects, objective 
reporting of results and findings and adequate statistical power to detect results. Research should 
not be judged solely on whether or not it is published in a leading journal.  The authors should 
provide the reader with enough and adequate details in the “Materials and Methods” in order to 
replicate the study if required. The study should also contribute to existing knowledge, ask and 
answer relevant research questions and ideally have comparison groups. Also, it should 
adequately explain findings and other reasons for the findings.  Research papers submitted for 
peer review are preferable. For a study to be regarded as being of high quality there needs to be 
evidence that the authors tried to minimize bias in their study designs. There are clearly many 
factors that need to be assessed before viewing a research article. 
The number of studies on the particular topic of interest was limited and the size of the samples 
was generally small thus affecting statistical power and possible credibility of the results 
obtained. A quality evidence base often requires consistency i.e., many research studies that
show similar findings. Consistency in the particular field of colistin doses and pharmacological
data was problematic as there are few studies, particularly in critically ill patients, on colistin.
However, in rare cases one study can provide convincing evidence due to the success of the 
findings in a well-designed and/or adequately powered study. However, the urgency for new 
information may incorrectly give a study higher than deserved credit as information is urgently
awaited and no other data exist. For example: Initial work done on the pharmacokinetics of
colistin in dialysis patients was a case report of a single patient on continuous venovenous 
haemodiafiltration (CVVHD) who was critically ill and required colistin (13). A lot of
pharmacological conclusions were drawn from this study and can clearly be erroneous as it was a 
single anecdotal report of the pharmacokinetics of colistin in this subset of patients.
Knowledge of the half-life of colistin was required in order to work out the creatinine clearance.
Many initial studies were performed in cystic fibrosis patients. This is a very specific group of
patients with specific pharmacodynamic and pharmacokinetic parameters. Since colistin use has 
now extended beyond cystic fibrosis patients and is now mainly used in Intensive Care Units 
(ICU’s) and often in patients with co-morbidity who are critically ill, more colistin studies are 
warranted.
Very little information on the predictive value of the SBT for mortality/outcome of patients 
infected with multi-drug resistant organisms exists. The study, published in the Journal of
Infection, conducted by researchers at the National University of Taiwan is one such study (14).
It correlated the titre obtained at peak, after administration of many classes of antibiotics, with
mortality. These findings were statistically significant. The study was powered to detect this 
difference and was a well-designed study, using multi-variate analysis.
Even though a large volume of information exists on colistin there is very little in the way of 
hard evidence especially concerning the pharmacokinetic and pharmacodynamic properties of 
the drug. This paucity of established information has had an effect on the strength of evidence 
that supports the current dosing recommendations. A lot of the current information is based on 
studies performed in the late seventies and early eighties. As a last resort many clinicians are 
basing and justifying their use of higher and higher doses on very few studies and more clinical 
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literature is that many papers and authors referred to one another, leading to difficulty in finding 
the origin of a stated fact.  
 
Much of the contemporary research is being conducted by a relatively small number of 
researchers. The positive aspect to this i.e., research produced by experts in the field is offset by 
the potential for the research strategy to be biased and unidirectional. The concept of 
bibliometric analysis applies here. This occurs when work done by a group of researchers is 
referred to by other authors when citing the research on that particular topic. Whilst the apparent 
importance of that research is enhanced there may be a degree of bias, and frequent references to 
a particular finding or study do not necessarily imply they are of high quality.  
 
The cited studies clearly show the discrepancies between the various findings proving that it was 
prudent to extend the estimation of the half-life due to the knowledge that in cystic fibrosis 
patients it is frequently shorter. 
 
Summary or interpretation of the literature: 
 
Current literature highlights the increase in multi-drug resistant isolates such as Klebsiella 
pneumoniae, Acinetobacter baumannii and Pseudomonas aeruginosa (8, 12, 21). In order to 
overcome this problem efforts have been made to find alternative treatment strategies and/or 
improve current knowledge as well as use existing medication to its full potential. This means 
either looking back at “forgotten” drugs such as the polymyxins and understanding how to use 
them optimally, or discovery of new drugs such as tigecycline that offer alternative antimicrobial 
options.  With the limited availability of alternatives there has also been a focus on combination 
therapy and the synergy that it can provide.  
 
Summary of the Drug, the Bug and the Test: 
Colistin: Colistin (polymyxin E) is a polymyxin antibiotic derived from various species of 
Paenibacillus polymyxa. It consists of two components: colistin A (polymyxin E1) and colistin B 
(polymyxin E2) (9). Colistin is administered as colistimethate sodium (colistimethate) which is 
also known as colistin methanesulphonate (8, 9, 17). Colistin methanesulphonate (CMS) is 
known to be unstable in aqueous solution as it hydrolyzes into a mixture of sulphomethyl 
derivatives plus colistin (12). Colistin is more biologically active than CMS and due to the 
instability of CMS it is uncertain how much is present in the administered product (3, 7, 9, 12). 
In-vitro studies have shown that colistin is bactericidal in a concentration-dependent manner and 
that a modest post-antibiotic effect occurs when high concentrations are used (17). 
 
While previous concerns regarding toxicity of colistin prompted clinicians to use alternative 
therapies, newer studies, as well as a lack of alternatives, have caused resurgence in the clinical 
use of colistin (6, 25). The most frequent adverse effects of polymyxins include nephrotoxicity 
and neurotoxicity, which are reversible upon cessation of the antibiotic (17). The polymyxins are 
known to be bactericidal. They disrupt the outer membrane of the organism causing cell lysis and 
death (17). The main indication for the use of colistin is the treatment of multidrug-resistant 
gram-negative bacteria that have reduced susceptibility to many other antimicrobial agents. The 
polymyxins were initially used in cystic fibrosis patients but are being required more regularly in 
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Much of the existing knowledge on pharmacokinetics and pharmacodynamics stems from 
research in animals as well as in cystic fibrosis patients. These data may be erroneous when 
applied to other patient groups as differences exist, such as shorter half-lives of drugs in cystic 
fibrosis patients (12, 13). Various small studies have also been conducted in different settings, 
with different patient profiles, using different study designs. Many of these studies have shown 
discrepant results thus causing confusion in the doses recommended for various patient groups. 
This is because the pharmacokinetic/pharmacodynamic (PK/PD) parameters have not yet been 
clearly defined. The results of the half-life of CMS and colistin for example, have shown major 
discrepancies. A study involving cystic fibrosis patients showed the half-life of CMS to be 2.1 
hours, and that of colistin to be 4.2 hours (22), while another study in this group of patients 
found that the half-life of CMS and colistin was 2.3 hours and 6.4 hours respectively (9). The 
dose recommendations of the various colistin preparations have been based on such information 
as well as studies on polymyxin B (7, 17, 23). When comparing the half-life determined 
previously to a more recent study in critically ill patients by Plachouras et al, it was shown that 
previous calculations of half-life could have been erroneous. Previous studies showed shorter 
values due to possible conversion of CMS to colistin before administration of the product. 
Plachouras et al estimated a typical half-life of colistin in critically ill patients to be 14.4 hours 
(22). 
 
Few studies have been performed in critically ill patients. Colistin use is increasing in this setting 
as well as in patients with renal impairment requiring various forms of dialysis. As PK/PD data 
in this group of patients is lacking, dosage recommendations have been problematic.  
 
Pharmacological levels of CMS and colistin have been assessed in a critically ill patients 
undergoing CVVHD in a study by Markou et al that found half-lives in critically ill patients at 
steady-state with varying renal function to be between 3.8-9.5 hours (15). As CMS is cleared by 
the renal route, whereas colistin is cleared by the non-renal route (17), a dosing strategy that 
maintains the size of the dose but extends the dosage interval has been proposed (13). The study 
in a single critically ill patient by Li et al showed that both colistin and CMS are removed by 
CVVHD (13). The authors did, however, state that the dose adjustment used in this patient 
should have been more modest. The study by Plachouras et al (22) also showed little correlation 
between colistin kinetics and creatinine clearance, supporting previous suggestions that colistin 
is cleared by the non-renal route. This study also suggested that current dosing may lead to 
colistin concentrations below the MIC breakpoints of usual gram-negative organisms after the 
first few doses of CMS. They suggest that initial doses could be increased without concomitant 
increase in toxicity. Loading doses as high as 12 million units have been suggested. Markou et al 
also performed a study in critically ill patients which suggested there was suboptimal dosing due 
to inadequate maximum concentrations of colistin being reached (15). 
 
Acinetobacter baumanni:  
This organism is a gram negative, aerobic non-fermenting bacterium that is a frequent cause of 
nosocomial infections such as ventilator associated pneumonia (VAP) and bacteraemia, 
especially in the ICU setting. Globally, there has been a rapid emergence of strains of 
Acinetobacter baumannii that are resistant to many antibiotic classes. This may be due to the fact 
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therapeutic strategies for treatment (5). Interest in colistin has arisen as it has become one of the 
only remaining antimicrobial options in some of these pan-drug resistant strains (5, 11, 20, 30). 
Resistance to the polymyxins is uncommon. Resistance has, however, been reported in certain 
instances where colistin has been used as a prolonged treatment for multidrug resistant 
organisms (17). Resistance to colistin can be due to modification of the lipid A component of the 
outer membrane, proteolytic destruction of the drug, as well as removal of the antibiotic by an 
efflux pump (1). It is important to consider sub-optimal dosing as a cause of emergence of 
colistin resistant isolates.  
 
The Serum bactericidal test (SBT):  
This microbiological assay is an in vitro test that attempts to measure the in-vivo activity of an 
antimicrobial agent. The highest titre (greatest dilution of the patient’s serum) that exerts a 
bactericidal effect on the organism is the serum bactericidal titre. This method of testing 
incorporates the pharmacodynamic and pharmacokinetic properties of the antimicrobial agent in 
question (2, 26). There are both advantages and disadvantages of microbiological and 
pharmacological assays. While pharmacological assays measure drug levels using High 
Performance Liquid Chromatography (HPLC) for instance, the SBT measures the final effect of 
the drug, which is bacterial death. Both methods need to be correlated with the clinical outcome 
of the patient for the result to be relevant. This has been found in pharmacological assays of 
other drugs such as aminoglycosides, where measuring peak levels has been shown to provide a 
useful therapeutic monitoring tool. Such a measurement has not yet been established for colistin. 
Pharmacolocical asays are important to determine the PK of various compounds such as CMS 
and colistin. The microbiological assay is unable to distinguish the colistin formed in-vitro 
(while performing the assay) to that formed in-vivo. It has been used in the past to confirm that 
bacterial eradication has been achieved but this has not been correlated with clinical outcomes 
(10, 18). The prognostic value and clinical relevance of microbiological assays have been 
questioned in the past. However, it is thought that a bactericidal effect is crucial when 
considering patients with deep-seated infections such as endocarditis (18). No previous published 
attempt has been made to look at SBT’s in patients on colistin. A study conducted at the National 
Taiwan University showed how the SBT can be used to predict patient outcome (14). This study 
aimed to determine the predictive value of the SBT for mortality in patients infected with multi-
drug-resistant A.baumannii. Patients were treated with various antibiotics/antibiotic 
combinations including carbapenems, ciprofloxacin, aminoglycosides and sulbactam. Colistin 
was not used in this study. The authors showed that the peak serum bactericidal titre negatively 
correlated with mortality rate (correlation coefficient -0.43). The survival rate in patients with 
peak SBT titres of ≥ 16, ≥ 8, ≤4 was 100%, 87.5% and 42.4% respectively (p=0.001). Given this 
strong association, it would be clinically relevant to compare SBT’s in patients on standard and 
adjusted doses of colistin in order to determine the efficacy of the adjusted renal dose.  
 
Due to the limited options of antibiotics available when treating pandrug-resistant organisms, a 
number of studies have been performed that assessed combination therapy with colistin for the 
treatment of Acinetobacter baumannii infections. This was done to assess synergy and possibly 
offer hope of preventing the emergence of resistance. The method of synergy testing used in 
these studies included checkerboard and time kill methods and used colistin in combination with 
rifampicin, minocycline, ceftazidime, meropenem, azithromycin, doxycycline, ampicillin-
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may be promising evidence to support the combination of colistin and rifampicin (19, 24, 27). 
Results using other drugs, not in combination with, colistin have been inconclusive (4, 28, 29, 





Identification of gaps and/or needs for further research: 
 
• More information on the other active metabolites of colistimethate. 
• Information on the exact effect of dialysis on colistin as well as more data on how the 
dialysis affects pharmacological levels of colistin. Outcome data stratified according to 
type of dialysis used (as well as dose administered) is urgently required. 
• Generally there are few randomized control studies on the PK/PD parameters of colistin. 
The pharmacodynamic parameters, such as AUC/MIC and %T/MIC, that are most 
applicable to colistin need to be defined and correlated with clinical efficacy.  This could 
affect dosing practices, for instance, if dosing with high peak levels once a day would be 
more beneficial than more frequent dosing. 
• More studies are required on the SBT and data on whether it can be used as a tool to 
assess patient outcome in various population groups. 
• Loading doses have frequently been addressed as potential improvements to dosing. No 
data exist on their value, or their margin of safety or concentration needed. 
• More information on synergy and possible combinations of other medication with 
colistin. It has been shown that resistance to colistin has already emerged. Alternative 
treatment approaches need to be investigated. 
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Standardized dosing regimens for colistin in critically ill patients with renal impairment 
requiring dialysis, are lacking. This is due to the paucity of pharmacokinetic and 
pharmacodynamic data.  Due to the dramatic rise in pan-resistant organisms that test 
sensitive only to colistin, information regarding its efficacy at the current recommended 
dosages is crucial. Colistin drug level measurements have recently been attempted but have 
not, as yet, been confidently correlated with microbiological and clinical outcomes. This 
study aims to determine microbiological efficacy of colistin at various time points after 
colistin dose administration by using the bactericidal titre of the patient’s serum against a 
standardized laboratory strain of Acinetobacter baumannii. Serum bactericidal titres from 
patients with renal impairment dosed according to their degree of renal impairment or 
dialysis requirements were compared to titres achieved in patients with normal renal 
function receiving a standard dose. Our results show that this microbiological assay, albeit 
relatively crude, shows a favourable correlation between the titres of the two patient 
groups throughout most of the dosing interval. The subset of patients on dialysis, however, 
who were dosed according to dialysis recommendations, tended toward lower titres at 
certain time points of the dosing interval. The data suggests that patients receiving doses 
adjusted for renal failure are achieving similar serum levels that could result in successful 





There has been a worldwide increase in the number of infections caused by multi-drug resistant 
gram negative bacteria such as Klebsiella pneumoniae, Pseudomonas aeruginosa and 
Acinetobacter baumannii. This has led to an increased use of polymyxins (such as colistin) 
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There are currently no standardized dosing regimens for colistin in critically ill patients with 
renal impairment requiring dialysis (1, 10). Guidelines that are currently in use for dosing at 
various degrees of renal impairment are not supported by adequate evidence. Anecdotal 
observations of therapeutic failure in patients with renal impairment have led to concerns that 
patients are being underdosed. In contrast, clinical experience shows that patients without renal 
failure who have Acinetobacter baumanii infections respond to the maximum recommended 
doses of colistin (Sanofi-Aventis product information for Coly-Mycin®, 1996). This study aimed 
to determine whether current maximum dosage recommendations in renal failure are sub-optimal 
by comparing serum bactericidal titres of patients receiving normal versus renally adjusted doses 
of colistin.  
 
Colistin has been available for use since the early 1960’s but fell out of favour because of 
concerns regarding toxicity. Interest in colistin has surged in the past 10 years due to problems 
with pan drug-resistant bacteria as well as new encouraging information about its toxicity profile 
(4). The main toxicities described with parenteral use include nephrotoxicity and neurotoxicity 
which may be avoided if correct doses are used. Both of these effects appear to be temporary and 
subside with a reduction in the dose or discontinuation of the drug (7, 14). New studies have 
revealed that colistin is not as nephrotoxic as previously believed and actually has a more 
favorable profile in terms of nephrotoxicity than aminoglycosides (10). A clinical dilemma arises 
in patients with renal insufficiency and critically ill patients with severe co-morbidities as dosing 
guidelines have not been adequately evaluated (8). There is also a paucity of information 
regarding the appropriate dosing regimens for patients requiring haemodialysis or continuous 
renal replacement therapy (10). The Coly-Mycin® product information from Sanofi-Aventis has 
guidelines on dosing in renal failure based on studies by Kucers and Bennet published in 1987. A 
data search failed to reveal any convincing new information. 
 
The antibacterial agent known as colistin is a polymyxin antibiotic consisting of two 
components: colistin A (polymyxin E1) and colistin B (polymyxin E2). Two different 
pharmacological formulations of coli tin are available commercially. The first, colistin sulphate, 
is for oral and topical use. The second, less toxic form, is sodium colistimethate (colistimethate) 
which is also known as colistin methanesulphonate (8, 9). The terms colistin and colistimethate 
are not interchangeable. Col stimethate is not stable either in-vitro nor in-vivo, and is hydrolyzed 
when in aqueous solution at 37°C, e.g., in plasma or broth, to a series of derivatives plus colistin, 
which have increased antibacterial activity (9, 10). The rate of hydrolysis depends on physical 
conditions such as pH and temperature (11).  Colistimethate is the inactive pro-drug of colistin 
(10). 
 
Pharmacokinetics of colistin:  
The pharmacokinetics of colistin has been studied using high-pressure liquid chromatography 
(HPLC) (9, 15). Most studies on the pharmacokinetics have been in patients with cystic fibrosis. 
Such studies may not be applicable to other patient groups e.g., half-lives in cystic fibrosis 
patients may be shorter (20). A study involving cystic fibrosis patients showed the half-life of 
colistimethate to be 2.1hrs, and that of colistin to be 4.2 hrs (11), while another study in this 
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More valuable information relating to critically ill patients is available in studies performed on 
this specific population of patients. In one of the first studies of this sort in 2005, levels were 
assessed in a critically ill patient undergoing continuous venovenous haemodialysis (CVVHD) 
(19). In this study, conversion of colistimethate to colistin was rapid and the half-lives of 
colistimethate and colistin were 6.8 and 7.5hrs respectively (19). The study by Markou et al 
found half-lives of colistin in critically ill patients at steady-state with various degrees of renal 
dysfunction to be between 3.8-9.5 hours (15). Plachouras et al estimated a typical half-life of 
colistin in critically ill patients to be 14.4 hours (20). This study also found that colistin clearance 
is not affected by creatinine clearance and thus colistin appears to be cleared by non-renal routes. 
The protein binding of colistin is reported as being low. A study in rats found that protein 
binding was about 55% in rat plasma (18). Peak serum levels after intravenous administration 
occur within 1 hour (15). Higher peak levels tend to occur in renal failure patients (11). 
 
Needless to say, the pharmacokinetic data relating to colistin are diverse, with no consensus on 
kinetic parameters. 
 
Pharmacodynamics of colistin:   
Colistin has rapid bactericidal activity, and is bactericidal in a concentration-dependent manner 
(6, 9, 12, 17).  Studies on the post antibiotic effect (PAE) of colistin have shown some 
concerning results indicating that even at high MIC’s there may be hetero-resistant sub-
populations in a number of the strains studied. The strains also showed unfavorable, 
unexplainable negative PAE’s (17) suggesting that mono-therapy or extended-interval dosage 
regimens (e.g., 24 hours) may not be optimal (17).  
 
Dosing of colistin: 
Due to concerns of drug resistance and therapeutic failure on lower doses there has been a trend 
to use maximum doses recommended for colistin (Table 1). The dose of colistin is based on 
international units (IU). One ampoule contains 80mg which is equivalent to 1 million IU. 
Various formulations of colistin are available in different countries and dose recommendations 
can be confusing as these are based on mg/kg dosing. International Units are preferable to avoid 
confusion and attempt to standardize dosing (5). Current recommendations in the UK and the 
USA recommend doses of up to an equivalent of 2MU per dose, either 12 hourly, 24 hourly or 
36 hourly according to re al impairment (5). Maximum doses of colistin stated in the Coly-
Mycin® package insert are 3MU at the recommended time intervals.  
 
The microbiological and clinical outcomes of this maximum dose have not yet been evaluated. 
The concern with this increase in dose is the concomitant increase in side effects particularly 
nephrotoxicity as reported in a study using a similar high dose regimen (14). Studies by 
Plachoras et al show no nephrotoxicity even with very high loading doses. It is possible that 
failure of colistin therapy could be due to inadequate levels in patients with renal failure 
receiving adjusted doses or the effect of dialysis on the drug levels. 
 
The Serum Bactericidal Test (SBT):  
This is an in-vitro test that attempts to measure the in-vivo activity of the antimicrobial agent. 
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organism is the serum bactericidal titre. This method of testing incorporates the 
pharmacodynamic and pharmacokinetic properties of the antimicrobial agent in question (1, 22).  
The clinical relevance of SBT testing has been questioned (16).  
 
A study performed at the National Taiwan University hospital undertook to determine the 
predictive value of the SBT for mortality in patients infected with multi-drug-resistant 
A.baumannii (13). Patients were treated with various antibiotics/antibiotic combinations 
including carbapenems, ciprofloxacin, aminoglycosides and sulbactam. Colistin was not used in 
this study. The authors showed that peak serum bactericidal titre negatively correlated with 
mortality rate (correlation coefficient -0.43). The survival rate in patients with a peak SBT titres 
of ≥ 16, ≥ 8, ≤4 was 100%, 87.5% and 42.4% respectively (p=0.001). Given this strong 
association, we believe that it will be valid and clinically relevant to compare SBT’s in patients 
on standard and renally adjusted doses of colistin in order to determine the efficacy of adjusted 
renal dosage (13).  
 
 
Materials and Methods 
 
Patients:  
Inclusion criteria:  
Any patient at Groote Schuur Hospital in Cape Town, South Africa requiring colistin therapy 
either as empiric therapy or for a confirmed infection with a pan drug-resistant organism during 
the period of June 2009 to March 2010.The decision to commence colistin was made by the 
attending physician.  
 
Exclusion criteria: 
Patients who had lipaemic or haemolysed serum as this could affect the interpretation of SBT’s 
that were determined according to visual turbidity. Patients or family members who declined 
consent to participation.  
 
Sample Collection (Clinical samples and patient information):  
Colistin was started according to the maximum dosages shown in Table 1. Initial blood samples 
were taken before colistin was commenced and then 2-3 days after the initial dose was given to 
allow a steady-state to be achieved (9). 
Sample size:  
In order to determine a two-fold difference in SBT level, which is considered significant, 
between the two groups (standard dose and renal dose) with 80% power and type 1 error of 0.05, 
seventeen patients were required per group. 
 
Blood samples were collected in clot activating tubes. Patients were divided into two groups 
according to their renal function. Creatinine clearance was estimated by calculation using the 
Cockcroft-Gault formula (20). This required knowledge of the ideal body weight (IBW) which 
was calculated using the Broca Index [IBW for men= (height in cm-100), IBW for women= 












 26  
Table 1:  Dose suggested according to renal function 
 
 Highest Doses recommended for 
Coly-Mycin® (26) 
Doses recommended by 
Sanford Guide to 
Antimicrobial therapy 2008 
(27) 
Cr Clearance ml/min Dose Dose 
Normal renal function: 3 million U 8 hourly 1-2 million U 8 hourly 
50-90 3 million U 12 hourly 2 million U 12 hourly 
10-50 3 million U daily 2 million U daily 
<10 3 million U 36 hourly 2 million U 36 hourly 
Anuric  1.5 million U after each episode of 
dialysis  
1 million U after dialysis 
CVVHD 3 million units 12 hourly (12) 2-3 million 48 hourly (1) 
 
 
Group 1 were patients with normal renal function defined as a clearance of ≥ 90 ml/min. Group 2 
included patients with renal impairment not requiring dialysis as well as patients requiring 
dialysis. Patients were sampled after they reached steady-state. Each colistin dose was 
administered as a short infusion over 30 minutes. Doses used were the highest doses 
recommended for Coly-Mycin™. Dosing of patients in Group 1 was 8 hourly.  Each patient had 
a sample taken before colistin was started (this is the colistin-free control). Blood was drawn at 
30min, 60min, 90min (to ensure peak determination) after completion of the colistin infusion, 
then at 4 hours and 8 hours (to demonstrate the trough level before the next dose was 
administered).  
 
Group 2: dose frequency varied according to the degree of renal impairment (Table 1). Blood 
was drawn at 30min,60min and 90 min and then  every 4 hours until the next dose was due i.e., 
at 4 hours, 8 hours and 12hours (trough level) if the dose frequency was 12 hourly for example.  
The degree of renal impairment, dose adjustment and type of dialysis (if utilized) was 
documented in all cases. Blood samples were placed on ice immediately (to terminate the 
conversion of colistimethate to colistin) and taken directly to the laboratory where the serum was 
first separated from the red blood cells in a refrigerated centrifuge (MISTRAL 3000i) at 3000 
rpm (664 x g) for 5min and then aliquoted into respective 1.5ml Eppendorf tubes (MERCK, 
South Africa) labeled according to time point drawn. The extra blood was used if the test 
required repeating, thus avoiding thawing and re-freezing the samples. Each sample was checked 
for sterility, i.e., growth of any organism that may affect turbidity of results. Serum was plated 
onto blood agar plates and incubated overnight at 35°C to exclude contamination. The serum was 
stored at -70°C. It has been shown that colistin is stable when frozen (18). Samples were thawed 
to room temperature just before processing. 
 
 
Laboratory setting:  
Microbiology Laboratory, National Health Laboratory Service (SANAS: South African National 
Accreditation Service) accredited, 
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Methods:  
The samples were tested individually to prevent premature thawing at room temperature. Testing 
was performed in sterile, plastic, flat-bottomed MICROLON ® microplate 96 well trays (Lasec 
SA, South Africa). The final volume in each well was 0.1ml.  
 
Inoculum preparation and inoculation of wells:  
The ATCC BAA-1605 strain available did not meet the study criteria thus a clinical strain isolated 
from a patient, that was resistant to all antibiotics tested except colistin and tobramycin was used. 
In no clinical situation were these two antibiotics used together.  
 
The degree of resistance was characterized (by doing Minimum Inhibitory Concentration testing 
using an Epsilometer E-TEST). This standard strain was used to ensure that results can be 
compared to each other with no bias due to variation in strain MIC. 
 
The CLSI (Clinical and Laboratory Standards Institute) recommendations required that the final 
inoculum of the reference strain in each test well were 5 x 105 cfu/ml. In order to achieve this 
concentration, preparation of the reference strain was required, as follows: 
 
First, the reference strain of Acinetobacter baumannii was subcultured three times on standard 
blood agar plates to ensure that the organism had optimal growth and metabolic status prior to 
drug exposure (16).  
Next, suspensions of the organism with a turbidity equivalent to that of a 1 McFarland standard 
was prepared after suspending the colonies into a pre-warmed (35°C) Tripticase Soya Broth 
(TSB -Greenpoint NHLS Media Laboratory, South Africa). These were incubated for 6 hours to 
ensure log-phase growth.  
Finally, the reference strain was diluted to achieve the optimal concentration. As a 1 Mcfarland 
standard contains approximately 3 x 108 cfu/ml, and the final concentration of the reference 
strain in each well once inoculated was 5 x 105 cfu/ml, a 1:30 dilution of the 1 McFarland 
standard was performed by adding 0.1ml of the reference strain suspension to 2.9ml of broth. 
This yielded an inoculum density of 1 x 107 cfu/ml, which was further diluted 1:20 by adding 5ul 
of this organism suspension to the 100ul (serum/TSB mixture) in the test well. This yielded a 
final inoculum of 5 x 105 cfu/ml in each well.  
 
For each timed sample from a patient e.g. patient A; Initial sample, a single row of a microwell 
plate (MWP) was used, with one MWP per patient. Firstly, 100uL of TSB was dispensed into 
wells 1-2 and 4-10 in a single row. Next, 5uL of ATCC strain was dispensed into the 1st TSB-
containing well, to serve as the positive growth control. The second well served as the negative 
growth control. Into the 3rd and 4th wells, 100uL of neat serum was dispensed. Serial doubling 
dilutions began from the 4th well using standard techniques with the final well for every sample 
being a 1:128 dilution. Next 5uL of the ATCC strain was added to wells 3 to 10, achieving a 
final volume of 105uL in all 10 wells.  
According to the CLSI document the volume of organism suspension added to the well must not 
exceed 10% of the total volume of the well as this may affect the dilution (16). 
 
For the next row, the above method was repeated for the next timed sample collected from the 
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(depending on the number of samples collected per patient), the microwell plate was incubated in 
air at 35°C for 18-24 hours. 
 
Reading of results:  
Wells were only read if there was definite turbidity in the positive growth control and no growth 
in the negative growth control. Twenty microlitres of fluid from every well containing no growth 
was sub-cultured onto Mueller-Hinton agar to assess the bactericidal activity of the drug. The 
plates were incubated in air at 35°C for 18-24 hours. The dilution that demonstrated 99.9% 
killing, i.e., 20ul of the 5 X 105 cfu/ml dilution containing fewer than 10 colonies on the plate, 




Thirty four patients were enrolled in this study, seventeen patients with normal renal function 
(Group 1) and seventeen with renal impairment (Group 2). Of the seventeen with renal failure six 
were anuric and required dialysis. Types of dialysis included Intermittent Haemodialysis (IHD) 
and Sustained Low Efficiency Dialysis (SLED). There were 3 patients in each dialysis sub-
group. Demographic and clinical data for the two groups are shown in Table 2. 
 
 







































Patients with normal renal function: Group 1 
Patient 1 116 D12 
ICU 
3MU 8hrly 3MU 8hrly 28 M CAZ,GEN  70 2 Perforated 
appendix 
Patient 2 119 C27 
ICU 
3MU 8hrly 3MU 8hrly 42 F SXT,ETP 60 60 6 Severe 
pneumonia 
Patient 3 197 C27 
ICU 
3MU 8hrly 3MU 8hrly 56 F ETP 60 60 4 Pontine 
lesion 
Patient 4 149 D12 
ICU 
3MU 8hrly 3MU 8hrly 35 M none 55 60 4 Severe 
pneumonia 
Patient 5 210 E26 3MU 8hrly 3MU 8hrly 35 F SXT  70 3 Pancreatitis 
Patient 6 105 D12 
ICU 
3MU 8hrly 3MU 8hrly 53 F AMC 80 65 5 Pancreatitis 
Patient 7 249 C27 
ICU 
3MU 8hrly 3MU 8hrly 31 F IMI  70 4 Bacterial 
meningitis 
Patient 8 250 G12 
D12 
3MU 8hrly 3MU 8hrly 61 F none  70 3 Pneumonia 
Patient 9 201 D12 
ICU 
3MU 8hrly 3MU 8hrly 25 M AMC  70 3 Polytrauma 
Patient 
10 

























3MU 8hrly 3MU 8hrly 38 M none  70 6 Sigmoid 
tumor 
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15 ICU trauma 
Patient 
16 






3MU 8hrly 3MU 8hrly 24 M IMI 65 75 3 Abdominal 
trauma 
 












1.5MU A/D 1.5MU after 
dialysis 















1.5MU A/D 1.5MU after 
dialysis 



















1.5MU A/D 1.5MU after 
dialysis 












1.5MU A/D 1.5MU after 
dialysis 












83 C12 3MU 12hrly 3MU 12hrly 36 M none  70 4 Polytrauma 
Patient 
31 
AN E26 1.5MU A/D 1.5MU after 
dialysis 
22 M IMI, VAN  70 3 Pneumonia 
Patient 
32 













and 1.5MU A/D 
3MU 12hrly 59 M CIP, MTZ  70 7 Pancreatitis  
CAZ, ceftazidime; GEN, gentamicin; SXT, trimethoprim-sulphamethoxazole; AMC, 
amoxicillin-clavulanate; IMI, imipenem; TZP, piperacillin-tazobactam; CIP, ciprofloxacin; 
VAN, vancomycin; AZM, azithromycin; AMK, amikacin; MTZ, metronidazole AN: 
Anuric 
 
Table 3 shows a summary of the SBT results. Tables 4 and 5 show the SBT’s obtained at peak 
and troughs respectively, in the two groups of patients. Sixteen of the seventeen patients (94.1%) 
in both Group 1 and 2 had a SBT of ≥ 16 at or near the peak (30, 60 or 90min). Eleven of the 
seventeen patients (64.7%) in Group 1, compared to 5/17 (29.4%) in Group 2 had SBT’s ≥ 16 for 
the entire duration of time until the next dose was administered (p= 0.086). Of the Group 2 
patients 2/17 did not have all of the samples taken but the SBT’s at the other sampling times 
were all ≥ 16. There were six anuric patients on dialysis in Group 2. All achieved peak SBT’s of 
≥ 16 at peak, however, no anuric patient on dialysis achieved a SBT ≥ 16 for the duration of drug 
exposure. Finally, 14/17 (82.4%) in Group 1 had SBT ≥ 16 at trough (just before next dose), 
compared to 6/17 (35.3%) in Group 2 which is statistically significant (p= 0.015). None of the 
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Table 3: Comparison of demographic features and Serum Bactericidal Titres in Group 1 
and Group 2 
 
 Group 1: Normal renal 
function (N=17) 





1: 1.1 1: 1.4 p= 0.731 
Age (yr): Mean  
 
38 (24-61) 49 (55-75) p= 0.021 





No. of patients in septic 




























Day of sampling: Mean 
 
3.9 (2-6) 4.4 (3-7) p= 0.276 
No. of patients on other 
concurrent or recent 
antibiotics (%) 
 
11/17 (64.5) 14/17 (82.4) p= 0.437 
No. of patients who had 
SBT ≥ 16 at peak (30-
90min) (%) 
 
No. of patients who had 
SBT ≥16 for the entire 
duration of sampling 
(%) 
 
No. of patients with 




















5/17 (29.4) but 2 patients 
NK 
0/6 (0) Anuric sub-group 
 
 
6/17 (35.3) but 3 ND 
0/6 (0) Anuric sub-group 













NK: (Not known) Patients who had a SBT of 16 or above for all other samples tested for 
that patient, but at certain sampling times had no blood taken (ND) 
ND: (Not done) Sample not done due to either patient refusal or inability to draw blood or 
patient demise 
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Table 4: Peak Serum Bactericidal Titres (SBT)  
 
Group 1: Normal renal function Group 2: Renal impairment 
(D – haemodialysis) 
Patient Titre Patient Titre 
Patient  1  16 Patient 18 ≥128 
Patient  2 * 64 Patient 19 * 16 
Patient  3 * 64 Patient 20 * 32 
Patient  4 64 Patient 21 * ≥128 
Patient  5 * 64 Patient 22 *(D) 32 
Patient  6 * 16 Patient 23 8 
Patient  7 * 16 Patient 24 * 64 
Patient  8 32 Patient 25 (D) 16 
Patient  9 16 Patient 26 128 
Patient 10 ≥ 128 Patient 27 *(D) 128 
Patient 11 4 Patient 28 * 128 
Patient 12 32 Patient 29 * 128 
Patient 13 * 16 Patient 30 16 
Patient 14 16 Patient 31 (D) 64 
Patient 15 32 Patient 32 * 128 
Patient 16 16 Patient 33 64 
Patient 17 16 Patient 34 * 16 
(D): Patient on Dialysis 
*: Patient Died 
 
Table 5: Trough Serum Bactericidal Titres (SBT)  
 
Group 1: Normal renal function Group 2: Renal impairment 
(D – haemodialysis) 
Patient Titre Patient Titre 
Patient  1 8 Patient 18 128 
Patient  2 * 64 Patient 19 * 8 
Patient  3 * 32 Patient 20 * 8 
Patient  4 32 Patient 21 * 128 
Patient  5 * 16 Patient 22 *(D) 8 
Patient  6 * 16 Patient 23 16 
Patient  7 * 16 Patient 24 * ND 
Patient  8 32 Patient 25 (D) 2 
Patient  9 16 Patient 26 64 
Patient 10 32 Patient 27 *(D) 2 
Patient 11 128 Patient 28 * 32 
Patient 12 16 Patient 29 * 64 
Patient 13 * 8 Patient 30 ND 
Patient 14 8 Patient 31 (D) ND 
Patient 15 16 Patient 32 * 8 
Patient 16 16 Patient 33 4 
Patient 17 16 Patient 34 * 8 
(D): Patient on Dialysis 
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All Group 1 patients received the maximum recommended dose and all anuric patients on 
dialysis received a dose of 1.5MU after dialysis.   
Only 8 of the 17 patients in Group 2 received the maximum recommended dose (Table 6). Of the 
patients who received this dose, 16/17 (94.1%) in Group 1 and all of patients in Group 2 
achieved an SBT at peak of ≥ 16 (p= 0.48). Twelve of the seventeen (70.6%) in Group 1 had an 
SBT ≥ 16 for the duration of dosing, compared to none in Group 2, which was significant 
(p=0.001).  Fourteen of the patients in Group 1 (82.4%) compared to none in Group 2 had 
Troughs of ≥ 16 (p=0.001). 
 
Of the patients in Group 2, seven of the seventeen patients received a higher dose than maximum 
recommended dose. Four of these seven patients had doses recommended 12 hourly but were 
given their dose 8 hourly. Two of the seven patients who were supposed to get a dose every 24 
hours received their medication 12 hourly. One of the seven patients who required 24 hour 
dosing received their colistin 8 hourly. Of these patients 6/7 (85.7%) reached a SBT of ≥ 16, 5/7 
(71.4%) achieved this for the entire duration, and 6/7 (85.7%) at Trough. 
 
Only two patients in Group 2 were dosed less frequently than recommended. One patient was 
supposed to get a dose 12 hourly but got it 24 hourly and the other was to get it every 24 hours 
but received it every 36 hours. In the less frequently dosed group 2/2 had SBT ≥16 at peak but 
0/2 had SBT ≥16 for the full dosing duration and trough. 
 
Mean day of sampling after commencement of dose was 3.9 (2-6) in Group 1, compared to 4.4 
(3-7) days in Group 2 (p= 0.276). The mean age in Groups 1 and 2 respectively were 38 (24-61) 
and 49 (55-75), (p= 0.021). Male to female ratios were 1:1,1 and 1: 1,4 in Group 1 and Group 2 
respectively  (p= 0.713). The mean ideal body weight for the two groups was equal (p= 1.0). The 
number of patients in septic shock in Group 1 and 2 was 1/17 and 2/17 respectively (p= 0.581). 
The number of patients on concurrent an ibiotics was 11/17 and 14/17 in Group 1 and Group 2 
respectively (p= 0.437). The number of patients on concurrent imipenem in the two groups was 
similar, 3/17 in Group 1 and 4/17 in Group 2 (p= 0.672). 
 
Table 6: Comparison of SBT’s in Group 1 and Group 2 according to dose administered 
 
 Group 1: Normal renal 
function 
Group 2: Renal impairment 








8/17 (47.1) p=0 .0005              
Peak  SBT ≥ 16: 16/17 (94.1) 8/8 (100)    p=0.48 
Entire duration SBT ≥ 16: 12/17 (70.6) 0/8 but 1 NK p=0.001 
Trough SBT ≥ 16: 14/17 (82.4) 0/8 but 2 ND p=0.001 
No. (%) receiving   lower 





Peak  SBT ≥ 16:  2/2 (100) 
Entire duration SBT ≥ 16:  0/2 (0) but 1 NK 
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No. (%) receiving higher 





Peak  SBT ≥ 16:  6/7 (85.7) 
Entire duration SBT ≥ 16:  5/7 (71.4) 
Trough SBT ≥ 16:  6/7 (85.7) 
NK: (Not known) Patients who had a SBT of 16 or above for all other samples tested for 
that patient, but at certain sampling times had no blood taken (ND) 
ND: (Not done) Sample not done due to either patient refusal, inability to draw blood or 
patient demise 
* calculated using Cockroft-Gault formula which uses ideal body weight (IBW) 
 
 
SBT’s were performed on each patient’s serum that was taken before the commencement of 
colistin . In both Groups, 2/17 had SBT’s of more than 1. Titres of 2 and 4 in Group 1, and 2 and 
8 in Group 2. 
 
Overall mortality in Group 1 was 6/17 (35%) and in Group 2 was 10/17 (59%). Of the patients 
on dialysis 50% (3/6) died. We were not able to establish whether death was directly attributable 
to sepsis or not as mortality in many cases was not temporarily related to the sepsis. Statistical 





Many factors play a role in determining the clinical outcome of a host invaded by a pathogen. 
These include: host factors, drug factors and organism factors (16). In this study we used a 
standard organism in order to assess the drug/host interaction specifically. While host variables 
could not be eliminated, we were able to show that they were not significantly different in the 
two groups studied. It can be assumed therefore that the differences seen in SBT’s are largely 
due to differences in drug administration.   
 
All patient variables, except age were shown not to be significantly different in the two groups. 
One of the host factors that could not be controlled, the bactericidal effect of human serum alone 
required assessment. This phenomenon occurs due to complement mediated lysis (3). 
Insignificant SBT’s were found with human serum alone without colistin. Other factors that 
could not be predicted or standardized related to in-vivo conditions, e.g., pH that may affect 
conversion of colistimethate to colistin as well as improvement/deterioration of renal function 
during the sampling process which may alter drug clearance. 
 
The collection, storage and processing of samples was standardized. Samples were frozen 
immediately after centrifugation in a refrigerated centrifuge to minimize hydrolysis of the drug. 
All laboratory procedures were carried out in a temperature controlled environment, with only 
one unfrozen specimen at a time.  
 
Sampling patients at exactly the same time after they had achieved steady-state was difficult to 











the time that sampling was required. No statistically significant difference in the mean day of 
sampling was found between the two groups.  
The strain of Acinetobacter used in the study had a colistin MIC of 0.25ug/ml. For an 
Acinetobacter isolate to be regarded as sensitive it needs to have an MIC of ≤2ug/ml. Possible 
clinical Acinetobacter isolates may have variable colistin MIC’s, and by choosing a very 
sensitive strain such as this, the SBT obtained would theoretically represent the best case 
scenario.  
A possible confounder in this study was the fact that many patients were on various concurrent 
antibiotics. Synergy studies show that there is no marked synergy of a polymyxin in combination 
with imipenem, rifampicin or azithromycin against certain strains of carbapenemase producing 
A.baumannii isolates (25).
A few studies have shown synergy when certain A.baumannii isolates are treated with colistin
and rifampicin (23, 24). None of the patients in this study were on rifampicin and colistin
concurrently, however, 3/17 patients in Group 1 were on concurrent imipenem and 4/17 patients 
in Group 2 were on concurrent imipenem (p=0.672). All patients on imipenem had peak SBT’s 
of ≥16. Timuryanak et al and other authors demonstrated that synergy occurs with colistin and 
meropenem/azithromycin, as well as partial synergy when colistin was combined with
doxycyline against multidrug resistant organisms. No patients in this study were on
meropenem/doxycycline or azithromycin (24).
Some patients had recently received other broad-spectrum antibiotics and others had renal failure 
which can affect clearance of these drugs. To minimize the effect of possible 
synergy/antagonism, a characterized strain of Acinetobacter baumannii that was resistant to all
locally available antimicrobials was used. This strain was sensitive to colistin ensuring that there 
would be a minimal effect on the SBT from the other concomitant antibiotics. The number of
patients on concurrent antibiotics in the two groups was not statistically different.
Serum Bactericidal Titres of patients receiving doses of colistin recommended for normal renal
function were compared to those receiving adjusted doses due to renal impairment. Based on
previous data showing an association between mortality and the SBT, the greatest benefit when
using an antibiotic was found when the SBT at peak was 16 or more (13). No information exists 
on what the significance of a SBT is at other time points of the dosing interval. Although a SBT 
predicts bacterial eradication, the clinical relevance of a SBT remains controversial (16). In vitro
bacterial eradication cannot predict clinical cure. One must remember that biological assays such
as this are unable to differentiate the amount of colistin present in the sample at the time of
collection from the colistin formed in vitro by hydrolysis of colistimethate during the 
microbiological assay (2). Bias was minimized by treating all samples in the same manner and 
using the SBT to compare the two groups. Microbiological assays are unable to directly
determine the serum concentration of the active components of colistin achieved with a 
particular dose. It is currently not known which metabolites of colistimethate are active thus 
when using a microbiological assay one is able to determine the collective effect of all the active 











The SBT results obtained suggest that the maximum recommended dose may be sufficient in
both groups to achieve an adequate peak. Group 2 includes all of the anuric patients who also
obtained SBT peaks of ≥ 16, all of whom received the recommended maximum dose. The major 
difference was noted when comparing the SBT at trough and those achieved for the entire 
duration of dosing. These results suggest that the maximum doses recommended may not be 
sufficient to obtain high SBT’s at times other than the peak. This has not yet been proven to be 
associated with clinical failure, but may explain the poor response observed in some patients 
receiving colistin. Only the SBT of ≥ 16 at peak has been shown to be a marker of improved 
outcome. The results of the SBT at peak in both groups including the dialysis patients were 
shown to be favourable. The concern is the possible lower levels achieved, as suggested by the 
lower SBT’s found for the duration of drug exposure. These low SBT’s were also found at
trough in Group 2, especially in the dialysis group. These findings may explain poorer outcomes 
observed in some patients on dialysis and may suggest that colistin is removed by dialysis and 
that higher doses may need to be considered in these patients. Whether higher SBT levels at
trough and throughout the dosing period are important to patient response to the colistin remains 
to be seen.
Not all patients in Group 2 received the recommended maximum dose and thus could not be 
included in the analysis of this dosing strategy, but it was interesting to see that all dosing 
strategies, maximum recommended, higher and lower than recommended, achieved acceptable 
SBT’s at peak. All groups had low SBT’s at trough and for the entire dosing duration except
most of the patients in Group 1 and those patients in Group 2 who were dosed higher than the 
maximum recommended dose. One may argue that this indicates that higher doses are necessary
in patients with renal impairment if trough levels and levels achieved throughout dosing are 
found to be important. Of these patients, 7/17 patients were given higher doses than
recommended and 2/17 were given lower doses. The miscalculations could have resulted due to 
calculation of creatinine clearance using the actual body weight (ABW) rather than ideal body
weight (IBW). IBW and not ABW should be used to calculate creatinine clearance. Using the 
ABW in obese patients may lead to overdosing and nephrotoxicity according to a study by
DeRyke in AAC July 2010 (21).
The mortality data has been shown for completeness however it must be stressed that the SBT’s 
achieved were determined using a characterized laboratory strain of Acinetobacter baumannii.
The patient’s own isolate was not used and not all patients cultured an Acinetobacter. Some 
patients cultured Pseudomonas and others were started on empiric therapy. Due to many other 
complicating patient factors and variable times of death relating to the sepsis requiring colistin
therapy, mortality could not be directly attributed to underdosing with colistin.
The prime reason for having undertaken this study is the lack of knowledge of the kinetics of 
colistin and its active metabolites. This has led to uncertainty about the efficacy of doses given to 
patients with renal impairment and those on dialysis. The use of a pharmacological assay on only 
one of the many possible active components of colistin may be misleading. The SBT, in contrast, 
is able to determine the actual activity of all the active metabolites that are having a bactericidal 
effect and thus provides at least in-vitro evidence of bactericidal activity. Whether this can then 
be correlated with clinical outcome is a separate issue. Ideally an SBT at which the drug is 











concentration for an aminoglycoside does) would be useful. This could then be used as a 
therapeutic drug monitoring tool or a correlate of efficacy. Regrettably, none of this data is 
available for colistin. 
…………………. 
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Table 7: Serum Bactericidal Titres at all time points Group 1 and Group 2 




60 90 240 480 720 1440 2160 
Group 1: Normal renal function 
Patient 
1 
1 16 16 16 16 8 
Patient 
2 
4 32 32 64 64 64 
Patient 
3 
1 32 32 64 64 32 
Patient 
4 
2 16 64 64 32 32 
Patient 
5 
1 32 64 64 32 16 
Patient 
6 
1 16 16 16 16 16
Patient 
7 
1 16 16 16 16 16 
Patient 
8 
1 32 32 32 32 32 
Patient 
9 
1 16 16 16 16 16 
Patient 
10 
1 64 64 128 64 32 
Patient 
11 
1 4 4 2 32 128 
Patient 
12 
1 16 32 32 16 16 
Patient 
13 
1 4 8 16 8 8 
Patient 
14 
1 16 8 16 8 8 
Patient 
15 
1 16 16 32 16 16 
Patient 
16 
1 8 16 16 16 16 
Patient 
17 















60 90 240 480 720 1440 2160 
Group 2: Renal impairment 
Patient 
18 
2 128 128 128 128 128 
Patient 
19 




1 16 32 16 16 16 8 
Patient 
21 
1 128 128 128 128 128 128 
Patient 
22 
1 8 8 16 32 16 16 32 
Patient 
23 
1 8 8 4 32 16 
Patient 
24 




1 2 4 8 16 16 16 8 
Patient 
26 
1 128 64 128 128 64 
Patient 
27 





8 32 128 32 32 32 
Patient 
29 
1 64 128 128 64 64 
Patient 
30 




1    ND 32 32 64 64 64 
ND ND ND 
Patient 
32 
1 16 128 128 32 8 
Patient 
33 
1 32 64 64 32 32 
ND 16 
  4 
Patient 
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1 8 16 16 16 16 8 
ND 
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